Loading...
Designer benzodiazepines gidazepam and desalkygidazepam (bromonordiazepam): What do we know?
Maskell, P.D. Wilson, G. Manchester, Kieran R.
Maskell, P.D.
Wilson, G.
Manchester, Kieran R.
Publication Date
2023-05
End of Embargo
Supervisor
Rights
Ā© The Author(s) 2023. Published by Oxford University Press. All rights reserved.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2023-01-24
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Designer benzodiazepines are one of the primary new psychoactive substances (NPS) threats around the world, being found in large numbers in post-mortem, driving under the influence of drugs (DUID) and drug facilitated sexual assault (DFSA) cases. Even though when compared to many other NPS types, such as opioids and cathinones, there are relatively few designer benzodiazepines being monitored. Recently a new NPS benzodiazepine has been reported in Europe, the USA and Canada, desalkygidazepam, also known as bromonordiazepam. This substance is a metabolite of the pro-drug gidazepam, a drug licenced for use in Ukraine and Russia under the name Gidazepam ICĀ®. In the paper we review what is currently known about the use, pharmacology and analytical detection of gidazepam, its metabolite desalkygidazepam, and their other possible metabolites.
Version
Accepted manuscript
Citation
Maskell PD, Wilson G and Manchester KR (2023) Designer benzodiazepines gidazepam and desalkygidazepam (bromonordiazepam): What do we know? Journal of Analytical Toxicology. 47(4): 324-331.
Link to publisherās version
Link to published version
Link to Version of Record
Type
Article